Through the clinical trial of 420 subjects, the sequential strengthening, which is also known as the “mixed fight” CanSino inhalation by the public, has good safety, and the total adverse reaction rate is lower than that of the inactivated vaccine homologous strengthening, and there is no serious Adverse reactions occur, but higher levels of neutralizing antibodies can be induced than homologous boosting of inactivated vaccines, and it is expected to be the preferred choice for boosting new crown vaccines.
Over the past three years, the new coronavirus has continued to mutate and is still ravaging the world. “Prevention” relies on vaccines, and vaccines using a new generation of technology will effectively block the spread of the virus on a global scale.
In response to the logic that the new crown virus invades from the respiratory mucosa, CanSino Biologics has innovated the global drug delivery method, using a nebulizer to atomize the new crown vaccine into tiny particles, which are inhaled into the respiratory tract and lungs, so as to effectively immunize against mutant strains. For the first time, the original innovation of China’s vaccine has taken the lead in the world.
Post time: May-27-2022